Wordt geladen...
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
PURPOSE. Angiogenesis is an important hallmark of breast cancer growth and progression. Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, has activity across a range of solid tumors. We evaluated the activity...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
AlphaMed Press
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228026/ https://ncbi.nlm.nih.gov/pubmed/20682606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0081 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|